These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37942878)

  • 21. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
    Lauck KC; Limmer A; Harris P; Kivelevitch D
    J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
    [No Abstract]   [Full Text] [Related]  

  • 22. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of oral finasteride enhanced occipital hair diameter index in different types of male androgenetic alopecia.
    Wang Q; Yang K; Lin J; Liu Q; Zhu Y; Li Z; Ni C; Lin J; Wu W
    J Am Acad Dermatol; 2023 Dec; 89(6):1292-1294. PubMed ID: 37604235
    [No Abstract]   [Full Text] [Related]  

  • 24. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.
    Hu R; Xu F; Sheng Y; Qi S; Han Y; Miao Y; Rui W; Yang Q
    Dermatol Ther; 2015; 28(5):303-8. PubMed ID: 26031764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
    Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
    World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
    Said MA; Mehta A
    Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finasteride and the Uncertainties of Establishing Harms.
    Moore TJ
    JAMA Dermatol; 2015 Jun; 151(6):585-6. PubMed ID: 25831198
    [No Abstract]   [Full Text] [Related]  

  • 30. The clinical applications of five-alpha reductase inhibitors.
    Loughlin KR
    Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
    Seale LR; Eglini AN; McMichael AJ
    J Drugs Dermatol; 2016 Apr; 15(4):414-9. PubMed ID: 27050696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
    J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finasteride and androgenic alopecia; from therapeutic options to medical implications.
    Motofei IG; Rowland DL; Tampa M; Sarbu MI; Mitran MI; Mitran CI; Stoian AP; Diaconu CC; Paunica S; Georgescu SR
    J Dermatolog Treat; 2020 Jun; 31(4):415-421. PubMed ID: 30897009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate, baldness drugs linked to sexual dysfunction.
    Kuehn BM
    JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
    [No Abstract]   [Full Text] [Related]  

  • 35. Persistent sexual side effects of finasteride: could they be permanent?
    Canguven O; Talib RA
    J Sex Med; 2013 May; 10(5):1441. PubMed ID: 23421328
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain.
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baconi D; Stefanescu E; Baleanu BC; Balalau C; Constantin V; Paunica S
    J Dermatolog Treat; 2016 Nov; 27(6):495-497. PubMed ID: 27046152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
    Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
    JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further Studies of Effects of Finasteride on Mood and Suicidal Risk.
    Baldessarini RJ; Pompili M
    J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):687-688. PubMed ID: 34735101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.